Health and Healthcare

AbbVie : ABBV

All AbbVie Articles

616 Articles

Chris Lange | Jul 3, 2016 at 7:38 AM EDT

How Major Pharma Is Faring After the Brexit

The broad markets are recovering in the wake of the Brexit and it really appears to be one big head…

Chris Lange | Jun 27, 2016 at 8:11 AM EDT

Short Sellers Increase Bets Against Major Pharmaceutical Stocks

The short interest data have been released for the June 15 settlement date. Pharmaceutical companies usually are involved in a…

Chris Lange | Jun 15, 2016 at 11:05 AM EDT

6 Biopharma Movers Making a Run on Wednesday

24/7 Wall St. has picked out the biggest movers and winners on Wednesday, particularly biopharma companies making serious runs in…

Chris Lange | Jun 14, 2016 at 11:15 AM EDT

Why Infinity Pharmaceuticals Crashed

Though Infinity Pharmaceuticals announced that its DYNAMO study met its primary endpoint of overall response rate, the stock was still…

Lee Jackson | Jun 13, 2016 at 8:15 AM EDT

Analysts Very Positive on 3 Top Stocks Following Jefferies Healthcare Conference

The Jefferies Healthcare Conference wrapped up in New York City last week, and the mood was reported as generally positive,…

Jon C. Ogg | Jun 10, 2016 at 9:05 AM EDT

Top Analyst Upgrades and Downgrades: Abbvie, Amazon, Cliffs Natural, Corning, Dynegy, Joy Global, Stanley Black & Decker and More

The top analyst upgrades, downgrades and initiations seen on Friday morning include Abbvie, Amazon.com, Cliffs Natural Resources, Corning, Dynegy, Joy…

Chris Lange | Jun 10, 2016 at 8:05 AM EDT

Major Pharma Has Short Sellers on the Run

The May 31 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Lee Jackson | Jun 7, 2016 at 8:25 AM EDT

4 Jefferies Franchise List Dividend Stocks to Buy Now

Moving some capital to lower volatility stocks makes sense as we head into summer. These four Jefferies Franchise Picks look…

Chris Lange | Jun 6, 2016 at 1:40 PM EDT

How Credit Suisse Views Major Pharma After ASCO

The ASCO annual meeting is absolutely making waves in the pharmaceutical industry. As a result, analysts are giving their two…

Chris Lange | Jun 2, 2016 at 10:50 AM EDT

Merrill Lynch Picks ASCO Winners

Merrill Lynch is one of the major firms that will be in attendance at the American Society of Clinical Oncology…

Lee Jackson | May 25, 2016 at 10:05 AM EDT

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue…

Chris Lange | May 25, 2016 at 8:15 AM EDT

Short Sellers Take Mixed Stance on Major Pharma

The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Chris Lange | May 12, 2016 at 7:40 AM EDT

ASCO Could Make or Break These 7 Cancer Drug Trials

The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society…

Chris Lange | May 11, 2016 at 8:45 AM EDT

Major Pharma Short Interest Continues to Recede

The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical…

Trey Thoelcke | May 5, 2016 at 7:35 AM EDT

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an…

1 … 30 31 32 33 34 … 42

AbbVie : ABBV

All AbbVie Articles

How Major Pharma Is Faring After the Brexit

Short Sellers Increase Bets Against Major Pharmaceutical Stocks

6 Biopharma Movers Making a Run on Wednesday

Why Infinity Pharmaceuticals Crashed

Analysts Very Positive on 3 Top Stocks Following Jefferies Healthcare Conference

Top Analyst Upgrades and Downgrades: Abbvie, Amazon, Cliffs Natural, Corning, Dynegy, Joy Global, Stanley Black & Decker and More

Major Pharma Has Short Sellers on the Run

4 Jefferies Franchise List Dividend Stocks to Buy Now

How Credit Suisse Views Major Pharma After ASCO

Merrill Lynch Picks ASCO Winners

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Short Sellers Take Mixed Stance on Major Pharma

ASCO Could Make or Break These 7 Cancer Drug Trials

Major Pharma Short Interest Continues to Recede

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

The American Chip Boom Picks Winners: TXN, INTC, and QRVO at Current Share Prices

NVIDIA is Acquiring ‘Dark Fiber’ Across the United States. Here’s Why That’s a Big Deal.

SpaceX Just Erased $1 Trillion in Value. Here’s Why the Worst Could Be Yet to Come.

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account

The American Chip Boom Picks Winners: TXN, INTC, and QRVO at Current Share Prices

NVIDIA is Acquiring ‘Dark Fiber’ Across the United States. Here’s Why That’s a Big Deal.

AbbVie : ABBV

All AbbVie Articles

How Major Pharma Is Faring After the Brexit

Short Sellers Increase Bets Against Major Pharmaceutical Stocks

6 Biopharma Movers Making a Run on Wednesday

Why Infinity Pharmaceuticals Crashed

Analysts Very Positive on 3 Top Stocks Following Jefferies Healthcare Conference

Top Analyst Upgrades and Downgrades: Abbvie, Amazon, Cliffs Natural, Corning, Dynegy, Joy Global, Stanley Black & Decker and More

Major Pharma Has Short Sellers on the Run

4 Jefferies Franchise List Dividend Stocks to Buy Now

How Credit Suisse Views Major Pharma After ASCO

Merrill Lynch Picks ASCO Winners

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Short Sellers Take Mixed Stance on Major Pharma

ASCO Could Make or Break These 7 Cancer Drug Trials

Major Pharma Short Interest Continues to Recede

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

The American Chip Boom Picks Winners: TXN, INTC, and QRVO at Current Share Prices

NVIDIA is Acquiring ‘Dark Fiber’ Across the United States. Here’s Why That’s a Big Deal.

SpaceX Just Erased $1 Trillion in Value. Here’s Why the Worst Could Be Yet to Come.

Featured Reads

If Social Security Cuts Benefits, Here's Who Might Get Hurt the Most

Peter Thiel Turned a $2,000 Roth IRA Into $5 Billion and Will Never Owe a Penny of Tax. The Same Rules Apply to Your Account